en · de · es · pt
assay-notes.peptides4800.com › Data › Selank Origin And Chemical Identity — Field Notes

Selank Origin And Chemical Identity — Field Notes

By Editorial Desk · published 2025-07-13 · last reviewed 2025-09-03 · Data

A practical reference on Selank: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-09-03 and is reviewed periodically as new material appears.

Selank Origin and Chemical Identity

Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.

The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.

Selank Background and Peptide Chemistry

Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.

Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideAnalog of the tetrapeptide tuftsin
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProReported consistently across pharmacopoeial descriptions
AppearanceWhite to off-white lyophilized powderTypical form of research-grade material
SolubilityFreely soluble in waterAqueous buffers; poor in nonpolar solvents
Typical storage temperature-20 degrees CelsiusLyophilized powder; protect from moisture

Origins and Proposed Mechanisms

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.

Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.

Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.

Related pages on this site

Administration, Testing and Availability

Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.

Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.

Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.

Peptide Identity and Structure

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Analytical Methods And Storage Stability

Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.

Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.

Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.

Supporting material

=== Inkjet printing === A promising physical technique is inkjet printing, which allows for conductive materials to be deposited in a precise and reproducible fashion onto paper. As a proof-of-concept, Ko et al. developed a paper-based electrical chip using a home office printer, an ink made of carbon nanotubes, and magazine paper. Similarly, silver nanoparticles were printed into microfluidic channels to sense changes in the permittivity of fluids, revealing information about concentration and mixing ratios. Research groups have found, however, that these nanoparticle containing inks can self-aggregate on the paper due to uneven drying, which leads to non-uniform coverage and non-linear responses. A promising physical technique is inkjet printing, which allows for conductive materials to be deposited in a precise and reproducible fashion onto paper. In this regards, the controlled growth of nanoparticles can help to improve conductivity and sensing performances. As the seeds clusters grow and interconnect inside of the paper fibers, there properties and structure of the final material can be controlled through the process and chemical conditions. A typical growth process conditions consist dissolved metal ions in a reductive chemical environment. Once the nanoparticles have grown, they can be functionalized with recognition biomolecules to increase the specificity and sensitivity of the microfluidic devices. Inkjet printing is compatible with a wide variety of materials.

Hong Kong has a humid subtropical climate (Köppen Cwa), characteristic of southern China, closely bordering on a tropical monsoon climate. Summers are long, hot, and humid, with occasional showers and thunderstorms and warm air from the southwest. The humid climate of Hong Kong intensifies summer heat. Typhoons occur most often then, sometimes resulting in floods or landslides. Also rarely occurring are waterspouts and tornadoes, which occurred at Hong Kong International Airport on 26 September 2020 and at Victoria Harbour on 28 September 2024. Winters are short, mild and usually sunny at the beginning, becoming cloudy towards February. Frequent cold fronts bring strong, cooling winds from the north and occasionally result in chilly weather. Autumn is the sunniest season, whilst spring is generally cloudy. Snowfall has been extremely rare in Hong Kong; the last reported instance was on Tai Mo Shan in 1975. Hong Kong averages 1,709 hours of sunshine per year. Historic temperature extremes at the Hong Kong Observatory are 36.9 °C (98.4 °F) on 9 August 2026 and 0.0 °C (32.0 °F) on 18 January 1893, record highest daily minimum temperature there was 30.2 °C (86.4 °F) on 12 August 2026 and the lowest daily maximum temperature there was 3.2 °C (37.8 °F) on 16 January 1893. The highest and lowest recorded temperatures in all of Hong Kong are 39.8 °C (104 °F) at Sheung Shui on 9 August 2026, and −6.0 °C (21.2 °F) at Tai Mo Shan on 24 January 2016.

== Composition == According to a 2007 study published in the Journal of Ethnopharmacology, the composition of cannabis tea is affected by criteria including, but not limited to, the duration of time over which the cannabis is steeped, the volume of tea prepared, and the period of time for which the tea is stored before consumption. The study mentions the ways in which levels of THC and THCA impact variability of composition by changing the bioactivity of the beverage. Therefore, cannabis teas that include less bioactive cannabinoids, "based on HPLC peak area" will demonstrate varying compositions.

STE20/SPS1-related proline-alanine-rich protein kinase is an enzyme that in humans is encoded by the STK39 gene. This gene encodes a serine/threonine kinase that is thought to function in the cellular stress response pathway. The kinase is activated in response to hypotonic stress, leading to phosphorylation of several cation-chloride-coupled cotransporters. The catalytically active kinase specifically activates the p38 MAP kinase pathway, and its interaction with p38 decreases upon cellular stress, suggesting that this kinase may serve as an intermediate in the response to cellular stress. Some studies suggest that this gene might be linked to high blood pressure.

Sources: en.wikipedia.org

Supporting material

=== Optogenetics === Optogenetics allows control of biological events in a non-invasive manner. The field has advanced in recent years with a number of new tools, including those to trigger light sensitivity, such as the Blue-Light-Utilizing FAD domains (BLUF). BLUFs encode a 100 to 140 amino acid sequence that was derived from photoreceptors in plants and bacteria. Similar to other photoreceptors, the light causes structural changes in the BLUF domain that results in disruption of downstream interactions. Current research investigates proteins with the appended BLUF domain and how different external factors can impact the proteins.

== Recombinant chymosin == Because of the imperfections and scarcity of microbial and animal rennets, producers sought replacements. With the development of genetic engineering, it became possible to extract rennet-producing genes from animal stomach and insert them into certain bacteria, fungi or yeasts to make them produce chymosin during fermentation. The genetically modified microorganism is killed after fermentation and chymosin is isolated from the fermentation broth, so that the fermentation-produced chymosin (FPC) used by cheese producers does not contain any GM component or ingredient. FPC contains the identical chymosin as the animal source, but produced in a more efficient way. FPC products have been on the market since 1990 and are considered the ideal milk-clotting enzyme. FPC was the first artificially produced enzyme to be registered and allowed by the US Food and Drug Administration. In 1999, about 60% of US hard cheese was made with FPC and it has up to 80% of the global market share for rennet. By 2008, approximately 80% to 90% of commercially made cheeses in the US and Britain were made using FPC. The most widely used fermentation-produced chymosin is produced either using the fungus Aspergillus niger or using Kluyveromyces lactis. FPC contains only chymosin B, achieving a higher degree of purity compared with animal rennet. FPC can deliver several benefits to the cheese producer compared with animal or microbial rennet, such as higher production yield, better curd texture and reduced bitterness.

The weathering of limestone, now exposed at the land surface, produces the lime-rich soils that are so prevalent in the fertile farmland of the Valley and Ridge province. During this continental break-up, around 600 million to 560 million years ago, volcanic activity was present along the tectonic margins. There is evidence of this activity in today's Blue Ridge Mountains. Mount Rogers, Whitetop Mountain, and Pine Mountain are all the result of volcanic activity that occurred around this time. Evidence of subsurface activity, dikes and sills intruding into the overlying rock, is present in the Blue Ridge as well. For instance, mafic rocks have been found along the Fries Fault in the central Blue Ridge area of Montgomery County, Virginia. One of the best examples of mafic rocks from the breakup of Rodinia is the Catoctin Formation. Erupted during the final stages of rifting associated with Rodinia (570–550 Ma), these rocks where later metamorphosed into Greenstone.

Sources: en.wikipedia.org

Frequently asked questions

What is Selank?

Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.

How does it relate to tuftsin?

The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.

Is Selank an approved medicine?

It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.

What is selank?

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.

Network